30 December 2017 - Medications that can inhibit the growth of two "catastrophic cancers" will next week be made available to Australians at a tiny fraction of the original price.

Health Minister Greg Hunt has announced the listing of cancer medicines alectinib (Alecensa) and carfilzomib (Kyprolis), whose manufacturers usually command more than $100,000 per court of treatment.

Listing these medicines on the Pharmaceutical Benefits Scheme means that from January 1, patients will pay only a maximum of $39.50 per script, with concessional patients paying just $6.40.

Read The Age article